Laura James hopes the final phase of research will lead to FDA approval of the rapid test. Credit: University of Arkansas for Medical Sciences.

The University of Arkansas for Medical Sciences (UAMS) in the US has commenced the final study of the first rapid diagnostic test for acetaminophen toxicity, after securing a grant of $3.2m.

The most common drug intended for fever and pain, Acetaminophen is also said to be the most common cause of liver failure in the US.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The three-year National Institutes of Health (NIH) Small Business Technology Transfer (STTR) grant will enable the inventors of the test, Laura James (MD), Jack Hinson (PhD) and Dean Roberts (PhD) from UAMS, to carry out the study’s final phase.

This phase will include the final development of the new AcetaSTAT blood test as well as a multisite clinical trial to assess its performance.

AcetaSTAT is a rapid assay for diagnosing acetaminophen liver injury. It is capable of detecting blood markers for injury from an overdose of the drug in about 20 minutes.

Acetaminophen Toxicity Diagnostics (ATD) developed the new laboratory test along with UAMS and Arkansas Children’s Hospital.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

University of Texas Southwestern Medical Center liver disease specialist William Lee is one of the trial’s co-investigators and was involved in the earlier testing of the assay.

Lee said: “I have been impressed that the assay provides a reliable yes/no answer as to whether acetaminophen is responsible for the liver injury.

“I look forward to seeing AcetaSTAT being available in any Emergency Department worldwide. Having the test will ensure that more patients receive the right diagnosis and appropriate treatment.”

James assembled an interdisciplinary team, across multiple centres, to carry out the clinical trial of the test.

UAMS plans to seek approval from the US Food and Drug Administration (FDA) for the blood test.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact